Early Detection of Metastatic Relapse and Monitoring of Therapeutic Efficacy by Ultra-Deep Sequencing of Plasma Cell-Free DNA in Patients With Urothelial Bladder Carcinoma

Christensen et al. (Mon,) studied this question.

www.synapsesocial.com/papers/69d8b0925c3030ff03d1a553 — DOI: https://doi.org/10.1200/jco.18.02052

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Monitoring Treatment Response and Metastatic Relapse in Advanced Bladder Cancer by Liquid Biopsy Analysis· 2017 · 173 citations
2. Postoperative Nomogram Predicting Risk of Recurrence After Radical Cystectomy for Bladder Cancer· 2006 · 459 citations
3. Multicenter Assessment of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer· 2014 · 296 citations
4. Limits of Tumor Detectability in Nuclear Medicine and PET· 2012 · 99 citations
5. Somatic <i>ERCC2</i> Mutations Correlate with Cisplatin Sensitivity in Muscle-Invasive Urothelial Carcinoma· 2014 · 618 citations